肿瘤性骨软化症:镓-68 DOTANOC PET/CT 扫描在识别致病病灶及其管理中的作用
该研究纳入17例临床和生化提示低磷血症且成纤维细胞生长因子-23升高的肿瘤性骨软化症患者,行68Ga-DOTANOC PET/CT扫描。扫描共发现52个病灶,其中37个摄取值增高;26个为非特异性骨骼摄取(骨折或退行性变),11个在9例患者中因高SUVmax、较大病灶及伴软组织成分被高度怀疑为致病病灶;后续CT/MRI显示7/9例患者有吻合病灶,经手术或活检病理证实为磷酸盐尿性间叶肿瘤。结论认为骨折/骨相关病灶与致病病灶的SUVmax存在重叠,非致病病灶SUVmax倾向于较低且无软组织成分;在多发摄取值增高病灶中,应仔细审阅68Ga-DOTANOC PET/CT以定位致病病灶,手术切除是最佳治疗,骨量减少/骨健康差无法手术者RFA为替代方案。
要点
- 多发骨骼摄取病灶中,骨折或退行性变所致非特异性摄取可与致病病灶的SUVmax重叠,后者倾向于SUVmax较低且无软组织成分。
- 致病病灶倾向表现为摄取值高、体积较大、非骨折部位且伴软组织成分的骨骼病灶。
- 发现致病病灶后手术切除是最佳治疗,骨量减少/骨健康差无法手术者RFA可作为替代。
核心结论
- 骨折/骨相关病灶与致病病灶的SUVmax存在一定重叠,多数非致病病灶SUVmax倾向于较低且无软组织成分。
- 在此情况下,摄取值高、体积较大、非骨折且伴软组织成分的病灶可能有助于在多发病灶中识别致病病灶。
- 发现致病病灶后,手术切除是最佳治疗;因骨量减少/骨健康差无法手术者,RFA是手术的替代方案。
研究设计与样本
- 本研究为单臂诊断性研究,纳入17例(男8例、女9例)临床和生化提示低磷血症且成纤维细胞生长因子-23升高的肿瘤性骨软化症患者。
- 所有患者行68Ga-DOTANOC PET/CT扫描,采用定性及半定量参数识别致病病灶。
- 后续行CT/MRI检查,对吻合病灶行手术切除或活检,并经组织病理学验证。
关键影像表现/征象
- 68Ga-DOTANOC PET/CT共发现52个病灶,其中37个摄取值增高。
- 37个摄取值增高病灶中,26个为非特异性局灶性骨骼摄取(骨折或退行性变)。
- 11个摄取值增高的骨骼病灶分布于9例患者(1例3个病灶,其余8例各1个),表现为高SUVmax(范围1.5-15.4,均值7.0±4.6)、病灶大小0.9-5.0 cm(均值3.3±1.5)并伴软组织成分,被高度怀疑为致病病灶。
- 后续CT/MRI显示7/9例患者有吻合病灶,经手术切除或活检病理证实为磷酸盐尿性间叶肿瘤。
诊断标准与关键数值
- 致病病灶判定依据:摄取值高、病灶较大、非骨折部位且伴软组织成分。
- 11个高度怀疑为致病病灶的骨骼病灶SUVmax范围为1.5-15.4(均值7.0±4.6),病灶大小0.9-5.0 cm(均值3.3±1.5)。
- 26/37个摄取值增高病灶为非特异性局灶性骨骼摄取(骨折或退行性变)。
临床应用与阅片要点
- 对长期肿瘤性骨软化症患者,68Ga-DOTANOC PET/CT发现多发骨骼病灶时需仔细审阅,以在多个摄取值增高病灶中定位致病病灶。
- 骨折或退行性变所致非特异性骨骼摄取可与致病病灶的SUVmax重叠,判读时需结合病灶大小、是否位于骨折部位及有无软组织成分。
- 发现致病病灶后手术切除是最佳治疗;因骨量减少/骨健康差无法手术者,RFA是替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to evaluate the role of 68Ga-DOTANOC positron emission tomography (PET)/CT scan in localization of culprit lesion for biopsy and required intervention [surgical excision/radiofrequency ablation (RFA)] in patients with long-standing oncogenic osteomalacia (OOM)/tumour-induced osteomalacia.
METHODS: 17 patients (8 males and 9 females) underwent 68Ga-DOTANOC PET/CT scan. The patients referred with clinical and biochemical evidence of hypophosphatemia and raised fibroblast growth factor-23. Qualitative and semi-quantitative parameters were used to identify culprit lesions.
RESULTS: 68Ga-DOTANOC PET/CT scan revealed 52 lesions in 17 patients, and 37/52 of these lesions were tracer avid. 26/37 lesions were non-specific focal tracer-avid skeletal lesions (fractures or degenerative changes). 11/37 tracer-avid skeletal lesions present in 9 patients (3 lesions in 1 patient and 1 each in rest of the 8 patients) were highly suspicious for culprit lesions in view of high maximum standardized uptake value (SUVmax) (range 1.5-15.4; mean 7.0 ± 4.6), lesion size (0.9-5.0 cm; mean 3.3 ± 1.5) and associated soft-tissue component. During subsequent imaging with CT/MRI, 7/9 patients showed concordant lesions which were excised or biopsied and histopathologically verified as phosphaturic mesenchymal tumours. Surgical excision was resorted to in most of the detected lesions, and RFA was performed in one patient.
CONCLUSION: There is some overlap in SUVmax between fracture-/bone-associated lesions and culprit lesions with a tendency of most non-culprit lesions to have lower SUVmax and no associated soft-tissue component. In such scenario, intensely tracer-avid, larger non-fracture lesions with soft-tissue component may lead to identification of culprit lesion among multiple lesions. Following detection of culprit lesion, surgical removal is the best treatment. RFA is alternative to surgery in cases where surgery is not possible owing to osteopenia/poor bone health. Advances in knowledge: The main challenge in patients of long-standing OOM is the presence of multiple skeletal lesions (both tumour- or tracer-avid fractures), and it is confusing to identify culprit lesion. This was noted in our study with 68Ga-DOTANOC and has not been mentioned in studies performed with 68Ga-DOTATATE/TOC PET/CT. In such scenario, 68Ga-DOTANOC PET/CT needs to be reviewed and read thoroughly to localize the culprit lesion out of the multiple tracer-avid lesions.
引用
- Singh D, Chopra A, Ravina M, et al. Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br J Radiol. 2017. PMID: 28181822. doi:10.1259/bjr.20160811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。